Amid significant strategic shifts and infrastructural investments, KBI Biopharma has decided to discontinue mammalian drug substance manufacturing at its Geneva, Switzerland facility. This move comes following a period of substantial upgrades and expansion, signaling a concerted effort to
September 6, 2024The biopharma sector is at an inflection point as the United States grapples with concerns about China's influence and potential risks posed by collaborations with Chinese military medical institutions. A legislative measure known as the BIOSECURE Act aims to address these apprehensions,
August 22, 2024Single-use systems (SUS) have revolutionized biopharmaceutical manufacturing, with single-use bioreactors (SUBs) leading the charge in recent decades. However, while the adoption of SUBs has plateaued, other forms of single-use technology (SUT) are gaining momentum. The landscape is evolving
August 15, 2024As climate change accelerates, the world is witnessing profound environmental transformations that significantly impact public health. These shifts don’t just cause rising ocean levels or sporadic extreme weather but also alter ecosystems in ways that trigger significant public health consequences.
August 12, 2024In a significant leap for diagnostic science, researchers from Tohoku University have unveiled a new approach leveraging composite polymer particles adorned with gold nanoparticles (GNDPs) to enhance the accuracy and sensitivity of tests for infectious diseases such as the influenza virus and
August 12, 2024Periodontitis remains one of the most common chronic inflammatory diseases affecting millions globally, characterized by an imbalance in the oral microbiome and prompted by pathogenic bacteria. Due to this imbalance, the body's immune response becomes inefficient, resulting in harm to
August 12, 2024